BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$75.96 USD
-0.46 (-0.60%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $75.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$75.96 USD
-0.46 (-0.60%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $75.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
PBYI vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Techne (TECH) Q1 Earnings
by Zacks Equity Research
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Techne (TECH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -6.82% and 4.44%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Techne (TECH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
New Strong Sell Stocks for October 3rd
by Zacks Equity Research
AFCG, AINC and TECH have been added to the Zacks Rank #5 (Strong Sell) List on October 3, 2023.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
AVTR, TECH and CPRI have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2023.
New Strong Sell Stocks for August 22nd
by Zacks Equity Research
AVTR, BHLB and TECH have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2023.
Techne (TECH) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Techne (TECH) Meets Q4 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
GSK vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
GSK vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
PBYI vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Techne (TECH) Q3 Earnings
by Zacks Equity Research
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Techne (TECH) Meets Q3 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 0% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.